PEG

HD-TAC7 is a potent PROTAC that targets HDAC1, HDAC2, and HDAC3 for degradation. Structurally, it integrates an HDAC-binding ligand and an E3 ligase recruiter, leading to selective modulation of HDAC activity. HD-TAC7 also influences NF-κB p65 levels in macrophages, making it useful for studying inflammatory pathways.

PROTAC BRD4 Degrader-19 is a molecule designed to induce degradation of the BRD4 protein through a PROTAC mechanism. It consists of ligands that bind BRD4 and an E3 ligase, facilitating targeted protein degradation, and is useful for studying BRD4-related pathways.

NUCC-0226272 is a potent PROTAC designed to induce degradation of EZH2, showing significant anti-proliferative properties. It is useful for investigating EZH2-related biological pathways.

PROTAC BRD4 Degrader-10 is a bifunctional molecule that links von Hippel-Lindau and BRD4 ligands. It facilitates BRD4 protein degradation in PC3 prostate cancer cells and can be conjugated with STEAP1 and CLL1 antibodies to enhance its targeting capabilities.

PROTAC BRD9 Degrader-6 is a highly potent molecule that targets BRD9 for degradation, making it useful for studying disorders related to the BAF complex. Its structure incorporates functional groups designed for efficient protein degradation.

α1A-AR Degrader 9c is a selective and reversible PROTAC molecule that targets the α1A adrenergic receptor for proteasomal degradation. Its functional groups are optimized for degrading α1A-AR and inhibiting cell proliferation, making it useful for studying receptor-related processes in prostate cell models.

PROTAC CYP1B1 Degrader-1, a derivative of α-naphthoflavone, is designed to selectively degrade CYP1B1, reducing cytochrome P450-mediated resistance. Its structure effectively targets CYP1B1 while showing selectivity over CYP1A2, making it useful for studying CYP1B1-overexpressing systems.

PROTAC EGFR Degrader 3 is a selective molecule designed to target EGFR for degradation, exhibiting strong cellular activity, particularly in H1975 and HCC827 cells. It operates through a lysosome-mediated degradation pathway for EGFR mutants.

HG-7-85-01-NH2 consists of an ABL inhibitor moiety connected to an IAP ligand through a linker, facilitating the formation of a SNIPER compound. This structural arrangement enhances targeted interactions and functional activity.